HRTX Heron Therapeutics
- 2.475
- +0.135+5.77%
Heron Therapeutics News
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webc
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.Nucor reported quarterly earnings of $3.46 per s
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday.Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply during Tuesday's session following upbeat quarterly result
Express News | Heron Therapeutics Shares Are Trading Higher After Capital One Initiated Coverage on the Stock With an Overweight Rating and $6 Price Target
Heron Therapeutics Initiated at Overweight by Capital One
Heron Therapeutics Initiated at Overweight by Capital One
Express News | Capital One Initiates Coverage On Heron Therapeutics With Overweight Rating, Announces Price Target of $6
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 20
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.
Heron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 81.82% Needham → $5 Reiterates Buy → Buy 03/13/2024 81.82% Needham $4 → $5 Maintains Buy 11/15/
Heron Therapeutics: A Strong Buy Based on Strategic Positioning and Growth Potential
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will
Heron Therapeutics Announces New Principal Accounting Officer
Investors in Heron Therapeutics (NASDAQ:HRTX) From Five Years Ago Are Still Down 88%, Even After 21% Gain This Past Week
It is a pleasure to report that the Heron Therapeutics, Inc. (NASDAQ:HRTX) is up 65% in the last quarter. But spare a thought for the long term holders, who have held the stock as it bled value ove
Heron Therapeutics Soars After 4Q Earnings Beat
Heron Therapeutics' stock was up 27% Wednesday after its fourth-quarter earnings beat expectations.
Biotech Finds Mid-Week Success Following Q4 Earnings Release
Sector Update: Health Care Stocks Slipping Late Afternoon
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each sliding around 0.5%. The iShares Biotechnology ETF (IBB)
Heron Therapeutics Shares Soar After Q4 Results Beat
Heron Therapeutics (HRTX) shares were up more than 31% in recent trading on Wednesday, a day after the company reported better-than-expected Q4 results. Late Tuesday, Heron posted Q4 net loss of $0.07
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersHeron Therapeutics (NASDAQ:HRTX) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings cam
HRTX, LUNA and ARQ Among Mid-day Movers
Earnings Call: Heron Therapeutics Outlines Progress and Forecasts Profitability
Heron Therapeutics (NASDAQ:HRTX), a biotechnology company specializing in pain management solutions, held its fourth-quarter earnings call for 2023, revealing a strategic reduction in operational expenses and significant progress in its product pipeline.
Analysis
Price Target
No Data
